These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22693703)

  • 1. Management of Parkinson's disease in the acute hospital environment.
    MacMahon MJ; MacMahon DG
    J R Coll Physicians Edinb; 2012 Jun; 42(2):157-62. PubMed ID: 22693703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
    Kuno S
    Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome.
    Ghosh R; Liddle BJ
    Postgrad Med J; 2011 Feb; 87(1024):125-31. PubMed ID: 21106801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of motor dysfunction in Parkinson's disease: an overview.
    Thobois S; Delamarre-Damier F; Derkinderen P
    Clin Neurol Neurosurg; 2005 Jun; 107(4):269-81. PubMed ID: 15885384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
    Diaz NL; Waters CH
    Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.
    Evans AH; Lawrence AD; Cresswell SA; Katzenschlager R; Lees AJ
    Mov Disord; 2010 May; 25(7):867-76. PubMed ID: 20461804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
    Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
    Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.